Zolgensma (onasemnogene abeparvovec-xioi) Clinical Coverage Criteria
Customize your policy alerts
Sign up for all fallon_community_health_plan_inc policy alerts
Know when fallon_community_health_plan_inc releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage criteria and prior authorization requirements for single-dose intravenous Zolgensma for pediatric patients under 2 years with SMA, applicable to Fallon Health products including Fallon Medicare Plus, NaviCare, and Community Care.
Effective April 1, 2025, MassHealth will transition the review and management of all APAD and APEC carve-out drugs, including Zolgensma, to the MassHealth Drug Utilization Review (DUR) Program.
Coverage Criteria for Zolgensma (onasemnogene abeparvovec-xioi)
Initial Therapy Criteria
A single-dose IV infusion of Zolgensma is considered medically necessary when clinical documentation supporting ALL of the following is submitted:
Permanent ventilator dependence defined as invasive ventilatory support (endotracheal tube or tracheostomy) or non-invasive respiratory assistance ≥16 hours/day for 14 continuous days in the absence of an acute reversible illness.
Summary of Clinical Evidence and Eligibility Features
Clinical evidence summarized from trials and registries demonstrating benefit in genetically confirmed SMA with 2 or 3 SMN2 copies
Age eligibility in trials varied (e.g., STR1VE-US <6 months, SPR1NT <6 weeks); trials used the one-time IV dose of ~1.1×10^14 vg/kg.
Repeat, or additional, dosing of Zolgensma beyond the single intravenous administration approved by the FDA is not supported by clinical trial data. The safety and effectiveness of repeat administration have not been evaluated and are therefore considered investigational. The policy likewise notes that use in patients with advanced SMA (for example, complete limb paralysis or permanent ventilator dependence) has not been evaluated and is considered investigational.
Clinical trial protocols for STR1VE‑US and SPR1NT excluded patients with an anti‑AAV9 antibody titer greater than 1:50 as measured by an ELISA binding immunoassay. Protocols allowed retesting within the 30‑day screening window; if the titer on repeat testing was ≤ 1:50, the patient could be enrolled and treated.
Coverage of services referenced in this policy depends on the member's specific benefit plan. Not all services mentioned are covered for all products or employer groups; providers must consult the member’s Evidence of Coverage or benefit documents because plan provisions, state mandates, or federal mandates may modify or supersede the policy language.
Use of Zolgensma in patients with more than 4 copies of SMN2 is designated as not medically necessary in this policy.
There are limited published data on outcomes for patients with four copies of SMN2 treated with Zolgensma; the evidence base is insufficient to fully assess benefits and harms in this population. In addition, the long‑term durability of benefit after gene replacement therapy beyond approximately five years remains incompletely characterized.
Coding and Key Clinical Values
| G12.0 | Infantile spinal muscular atrophy, type I [Werdnig-Hoffman] |
| G12.1 | Other inherited spinal muscular atrophy |
| G12.8 | Other SMAs and related syndromes |
| G12.9 | Spinal muscular atrophy, unspecified |
| J3399 | Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required
Prior authorization by a Fallon Health Medical Director is required for Zolgensma; for MassHealth ACO members with dates of service on or after April 1, 2025, prior authorization requests for Zolgensma must be submitted to the MassHealth Drug Utilization Review (DUR) Program prior to administration. This prior authorization is separate from any prior authorization that may be required for the member's inpatient or outpatient encounter.
- Submit prior authorization to Fallon Health Medical Director for Fallon Medicare Plus, NaviCare, and Community Care members.
- For MassHealth ACO members (DOS on/after 4/1/2025), submit the prior authorization request for Zolgensma to the MassHealth DUR Program for review and approval prior to administration.
- Prior authorization for Zolgensma is distinct from any encounter-level prior authorization for inpatient/outpatient services; Fallon remains responsible for encounter review.
Coding to include on prior authorization
When requesting prior authorization, reference the HCPCS code J3399 for onasemnogene abeparvovec-xioi and include the relevant SMA ICD-10 diagnosis codes (G12.0, G12.1, G12.8, G12.9) on the submission.
- HCPCS: J3399 — Injection, onasemnogene abeparvovec-xioi, per treatment.
- ICD-10: G12.0, G12.1, G12.8, G12.9 as applicable to the member's SMA diagnosis.
Prior authorization and payer-specific rules
Authorization and coverage depend on the member's specific plan type and applicable Medicare or MassHealth determinations; follow plan benefits and medical necessity criteria when submitting requests.
- Medicare Advantage determinations follow CMS NCDs and LCDs where applicable; Fallon may create internal criteria only when those are not established.
- For MassHealth members Fallon generally follows MassHealth Medical Necessity Guidelines; verify any MassHealth-specific processes (see MassHealth carve-out rules).
- Consult the member's Evidence of Coverage for product-specific coverage or exclusions.
Concomitant SMN‑modifying therapy not permitted
Concomitant use of SMN-modifying therapies (e.g., nusinersen [Spinraza], risdiplam [Evrysdi]) is not permitted; the member's medical record will be reviewed and any current authorizations for SMN‑modifying therapy will be terminated upon Zolgensma approval.
- Do not administer nusinersen or risdiplam concurrently with Zolgensma.
- Expect termination of existing authorizations for SMN‑modifying therapy once Zolgensma is approved.
Document prior or concurrent SMA therapies
Document any prior or concurrent SMA-directed therapies (e.g., prior nusinersen) in the medical record, as such information may be relevant to authorization decisions and follow-up.
- Include dates and dosing history of prior SMN‑modifying therapies.
- Note any participation in long‑term follow‑up or clinical trial regimens involving concomitant therapy.
Step therapy: not specified — verify plan rules
No step therapy sequencing is specified in this policy; follow applicable Medicare/MassHealth guidance and the member's benefit plan for any treatment‑sequencing requirements.
- If plan-level step therapy requirements exist, comply with those prior to Zolgensma authorization.
- When in doubt, verify with the member's Evidence of Coverage or payer policy.
Required clinical documentation for prior authorization
Clinical documentation submitted with the authorization must include the member's age at infusion, the neuromuscular specialist treating provider, genetic testing confirming biallelic SMN1 mutation and SMN2 copy number (2–4 copies), and anti‑AAV9 antibody titer determined by ELISA (≤1:50).
- Provide genetic test report showing bi‑allelic SMN1 mutation and documented SMN2 copy number.
- Include clinician name, specialty (neuromuscular), and justification for therapy.
- State member's exact age/date of birth and planned infusion date.
Laboratory documentation: Anti‑AAV9 titer and SMN2 copy number
Laboratory documentation of Anti‑AAV9 antibody titer testing (ELISA) and SMN2 copy number should be included, as trials excluded patients with Anti‑AAV9 titers >1:50 unless retesting within 30 days reduced the titer to ≤1:50.
- Submit Anti‑AAV9 antibody ELISA result with titer value; eligible if ≤1:50 or retest within 30 days demonstrating ≤1:50.
- Include SMN2 copy number test report performed with validated methodology.
Benefit plan verification required
Verify the member's specific benefit plan/Evidence of Coverage before treatment because not all services mentioned in this policy are covered for all products or employer groups; benefit plan provisions govern when they conflict with this policy.
- Check for any product-specific exclusions or limitations in the member's Evidence of Coverage.
- Recognize that state and federal mandates may supersede plan provisions for certain members.
Denial risks: age, advanced disease, antibody titer, repeat dosing
Denial risk exists if the member is 2 years of age or older at the time of infusion, has advanced SMA (for example, permanent ventilator dependence), has an Anti‑AAV9 antibody titer >1:50, or is being considered for repeat administration (repeat dosing is investigational).
- Confirm age <2 years on date of infusion; members ≥2 years risk denial.
- Confirm absence of advanced SMA/permanent ventilator dependence per policy definition.
- Provide Anti‑AAV9 ELISA titer ≤1:50; titers >1:50 are exclusionary unless retesting within 30 days shows ≤1:50.
- Repeat administrations are considered investigational and may be denied.
MassHealth ACO prior authorization routing (effective 4/1/2025)
For MassHealth ACO members with dates of service on or after April 1, 2025, prior authorization requests for Zolgensma must be submitted to the MassHealth DUR Program prior to administration; failure to submit to DUR may result in denial.
- Submit the Zolgensma prior authorization to the MassHealth DUR Program for MassHealth ACO enrollees (DOS on/after 4/1/2025).
- Ensure approval from DUR before scheduling infusion to avoid claim denial.
Anti‑AAV9 antibody exclusion and retest process
An Anti‑AAV9 antibody titer >1:50 was an exclusion criterion in key trials; a titer above 1:50 at screening suggests potential ineligibility or denial unless retesting within 30 days shows a titer ≤1:50.
- Provide initial Anti‑AAV9 ELISA result; if >1:50, arrange retesting within 30 days and submit the retest result if ≤1:50.
- Document assay method (ELISA) and lab performing the test.
Medicare coverage triggers — follow NCDs/LCDs
Coverage determinations for Medicare Advantage members follow CMS NCDs and LCDs; failure to meet applicable Medicare NCD/LCD or statutory criteria may result in non‑coverage.
- When CMS NCDs/LCDs apply, ensure documented alignment with those criteria on the prior authorization request.
- If Medicare criteria are absent or unclear, Fallon may apply internal criteria consistent with regulation.
MassHealth coverage triggers and risk of misalignment
For MassHealth members Fallon generally follows MassHealth Medical Necessity Guidelines; in the absence of MassHealth guidance Fallon may apply internal clinical criteria — lack of alignment with MassHealth rules could risk denial.
- Verify MassHealth Medical Necessity Guidelines when applicable.
- Be aware Fallon may create criteria where MassHealth guidance is silent; confirm requirements before dosing.
Background and Clinical Context
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by biallelic pathogenic variants in the SMN1 gene leading to deficiency of SMN protein and motor neuron degeneration. The number of SMN2 gene copies modifies clinical severity and was a key stratification factor in pivotal trials. Zolgensma (onasemnogene abeparvovec‑xioi) is an adeno‑associated virus serotype 9 (AAV9)‑based SMN1 gene replacement therapy approved by the FDA for pediatric patients less than 2 years of age with bi‑allelic SMN1 mutations; approval was supported by Phase 1 and Phase 3 trial data demonstrating improved motor function and survival compared with natural history, but long‑term durability and data in some subgroups remain limited.
Definitions and Key Terms
Revision History and Policy Updates
MassHealth will transition prior authorization review and management of APAD and APEC carve-out drugs, including Zolgensma, to the MassHealth Drug Utilization Review (DUR) Program; for dates of service on or after 2025-04-01, prior authorization requests for these drugs must be submitted to the MassHealth DUR Program prior to administration (Fallon remains responsible for inpatient/outpatient encounter review).
Origination date: 09/01/2021. The policy has undergone annual review with committee approvals noted on 06/22/2021 (TAC; origination), 12/06/2022, 04/23/2024 (added coverage for 4 copies of SMN2 effective 05/01/2024), 04/29/2025 (added Medicare and MassHealth variations; noted MassHealth transition effective 04/01/2025), and 04/28/2026 (annual review; no changes to coverage criteria). The document records the MassHealth DUR Program transition effective 04/01/2025 as a material administrative change.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.